{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:02:01Z","timestamp":1792792921526,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12891-017-1625-y","type":"journal-article","created":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T14:34:33Z","timestamp":1497882873000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis"],"prefix":"10.1186","volume":"18","author":[{"given":"Makoto","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Deacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Eastell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,19]]},"reference":[{"key":"1625_CR1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/0002-9343(93)90218-E","volume":"94","author":"CD Conference","year":"1993","unstructured":"Conference CD. Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med. 1993;94:646\u201350.","journal-title":"Am J Med"},{"key":"1625_CR2","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1126\/science.289.5484.1504","volume":"289","author":"SL Teitelbaum","year":"2000","unstructured":"Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289:1504\u20138.","journal-title":"Science"},{"key":"1625_CR3","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1126\/science.289.5484.1508","volume":"289","author":"GA Rodan","year":"2000","unstructured":"Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science. 2000;289:1508\u201314.","journal-title":"Science"},{"key":"1625_CR4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","volume":"31","author":"RA Adler","year":"2016","unstructured":"Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American society for bone and mineral research. J Bone Miner Res. 2016;31:16\u201335.","journal-title":"J Bone Miner Res"},{"key":"1625_CR5","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S0021-9258(17)42227-7","volume":"269","author":"K Tezuka","year":"1994","unstructured":"Tezuka K, Tezuka Y, Maejima A, Sato T, Nemoto K, Kamioka H, et al. Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. J Biol Chem. 1994;269:1106\u20139.","journal-title":"J Biol Chem"},{"key":"1625_CR6","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1126\/science.273.5279.1236","volume":"273","author":"BD Gelb","year":"1996","unstructured":"Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science. 1996;273:1236\u20138.","journal-title":"Science"},{"key":"1625_CR7","doi-asserted-by":"crossref","first-page":"13453","DOI":"10.1073\/pnas.95.23.13453","volume":"95","author":"P Saftig","year":"1998","unstructured":"Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A. 1998;95:13453\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1625_CR8","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1359\/jbmr.1999.14.10.1654","volume":"14","author":"M Gowen","year":"1999","unstructured":"Gowen M, Lazner F, Dodds R, Kapadia R, Feild J, Tavaria M, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res. 1999;14:1654\u201363.","journal-title":"J Bone Miner Res"},{"key":"1625_CR9","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1359\/jbmr.1999.14.11.1902","volume":"14","author":"Y Nishi","year":"1999","unstructured":"Nishi Y, Atley L, Eyre DE, Edelson JG, Superti-Furga A, Yasuda T, et al. Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation. J Bone Miner Res. 1999;14:1902\u20138.","journal-title":"J Bone Miner Res"},{"key":"1625_CR10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S8756-3282(99)00270-7","volume":"26","author":"LM Atley","year":"2000","unstructured":"Atley LM, Mort JS, Lalumiere M, Eyre DR. Proteolysis of human bone collagen by cathepsin K: characterization of the cleavage sites generating by cross-linked Ntelopeptide neoepitope. Bone. 2000;26:241\u20137.","journal-title":"Bone"},{"key":"1625_CR11","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1359\/jbmr.2003.18.5.859","volume":"18","author":"P Garnero","year":"2003","unstructured":"Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res. 2003;18:859\u201367.","journal-title":"J Bone Miner Res"},{"issue":"7","key":"1625_CR12","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.addr.2004.12.013","volume":"57","author":"Y Yasuda","year":"2005","unstructured":"Yasuda Y, Kaleta J, Br\u00f6mme D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev. 2005;57(7):973\u201393.","journal-title":"Adv Drug Deliv Rev"},{"key":"1625_CR13","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1517\/13543776.2011.616283","volume":"21","author":"J Wijkmans","year":"2011","unstructured":"Wijkmans J, Gossen J. Inhibitors of cathepsin K: a patent review (2004 - 2010). Expert Opin Ther Pat. 2011;21:1611\u201329.","journal-title":"Expert Opin Ther Pat"},{"key":"1625_CR14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrd.2016.132","volume":"15","author":"K Garber","year":"2016","unstructured":"Garber K. Two pioneering osteoporosis drugs finally approach approval. Nat Rev Drug Discov. 2016;15:445\u20136.","journal-title":"Nat Rev Drug Discov"},{"key":"1625_CR15","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.bone.2011.09.041","volume":"49","author":"Y Ochi","year":"2011","unstructured":"Ochi Y, Yamada H, Mori H, Nakanishi Y, Nishikawa S, Kayasuga R, et al. Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism. Bone. 2011;49:1351\u20136.","journal-title":"Bone"},{"key":"1625_CR16","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/jbmr.341","volume":"26","author":"R Eastell","year":"2011","unstructured":"Eastell R, Nagase S, Ohyama M, Small M, Sawyer J, Boonen S, et al. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study. J Bone Miner Res. 2011;26:1303\u201312.","journal-title":"J Bone Miner Res"},{"key":"1625_CR17","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/jbmr.2047","volume":"29","author":"R Eastell","year":"2014","unstructured":"Eastell R, Nagase S, Small M, Boonen S, Spector T, Ohyama M, et al. Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study. J Bone Miner Res. 2014;29:458\u201366.","journal-title":"J Bone Miner Res"},{"key":"1625_CR18","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1365-2125.2012.04307.x","volume":"74","author":"S Nagase","year":"2012","unstructured":"Nagase S, Hashimoto Y, Small M, Ohyama M, Kuwayama T, Deacon S. Serum and urine bone resorption markers and pharmacokinetics of the cathepsin K inhibitor ONO-5334 after ascending single doses in post menopausal women. Br J Clin Pharmacol. 2012;74:959\u201370.","journal-title":"Br J Clin Pharmacol"},{"key":"1625_CR19","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.bmcl.2007.12.047","volume":"18","author":"JY Gauthier","year":"2008","unstructured":"Gauthier JY, Chauret N, Cromlish W, Desmarais S, Duong LT, Falgueyret JP, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008;18:923\u20138.","journal-title":"Bioorg Med Chem Lett"},{"key":"1625_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2014.04.023","volume":"65","author":"Y Ochi","year":"2014","unstructured":"Ochi Y, Yamada H, Mori H, Nakanishi Y, Nishikawa S, Kayasuga R, et al. Effects of eight-month treatment with ONO-5334, a cathepsin K inhibitor, on bone metabolism, strength and microstructure in ovariectomized cynomolgus monkeys. Bone. 2014;65:1\u20138.","journal-title":"Bone"},{"key":"1625_CR21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bone.2016.02.014","volume":"86","author":"H Yamada","year":"2016","unstructured":"Yamada H, Ochi Y, Mori H, Nishikawa S, Hashimoto Y, Nakanishi Y, et al. Effects of 16-month treatment with the cathepsin K inhibitor ONO-5334 on bone markers, mineral density, strength and histomorphometry in ovariectomized cynomolgus monkeys. Bone. 2016;86:43\u201352.","journal-title":"Bone"},{"key":"1625_CR22","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/jbmr.1477","volume":"27","author":"T Cusick","year":"2012","unstructured":"Cusick T, Chen CM, Pennypacker BL, Pickarski M, Kimmel DB, Scott BB, et al. Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res. 2012;27:524\u201337.","journal-title":"J Bone Miner Res"},{"key":"1625_CR23","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1359\/jbmr.091035","volume":"25","author":"HG Bone","year":"2010","unstructured":"Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res. 2010;25:937\u201347.","journal-title":"J Bone Miner Res"},{"key":"1625_CR24","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/jbmr.1695","volume":"27","author":"B Langdahl","year":"2012","unstructured":"Langdahl B, Binkley N, Bone H, Gilchrist N, Resch H, Rodriguez Portales J, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res. 2012;27:2251\u20138.","journal-title":"J Bone Miner Res"},{"key":"1625_CR25","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/j.1365-2125.2012.04471.x","volume":"75","author":"SA Stoch","year":"2013","unstructured":"Stoch SA, Zajic S, Stone JA, Miller DL, van Bortel L, Lasseter KC, et al. Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers. Br J Clin Pharmacol. 2013;75:1240\u201354.","journal-title":"Br J Clin Pharmacol"},{"key":"1625_CR26","first-page":"487","volume":"74","author":"R Eastell","year":"1992","unstructured":"Eastell R, Calvo MS, Burritt MF, Offord KP, Russell RG, Riggs BL. Abnormalities in circadian patterns of bone resorption and renal calcium conservation in type I osteoporosis. J Clin Endocrinol Metab. 1992;74:487\u201394.","journal-title":"J Clin Endocrinol Metab"},{"key":"1625_CR27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S8756-3282(02)00791-3","volume":"31","author":"P Qvist","year":"2002","unstructured":"Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone. 2002;31:57\u201361.","journal-title":"Bone"},{"key":"1625_CR28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00774-013-0517-y","volume":"32","author":"M Tanaka","year":"2014","unstructured":"Tanaka M, Hashimoto Y, Sekiya N, Honda N, Deacon S, Yamamoto M. Effects of novel cathepsin K inhibitor ONO-5334 on bone resorption markers: a study of four sustained release formulations with different pharmacokinetic patterns. J Bone Miner Metab. 2014;32:447\u201354.","journal-title":"J Bone Miner Metab"},{"key":"1625_CR29","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.bone.2015.07.016","volume":"81","author":"M Tanaka","year":"2015","unstructured":"Tanaka M, Hashimoto Y, Hasegawa C. An oral cathepsin K inhibitor ONO-5334 inhibits N-terminal and C-terminal collagen crosslinks in serum and urine at similar plasma concentrations in postmenopausal women. Bone. 2015;81:178\u201385.","journal-title":"Bone"},{"key":"1625_CR30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00198-015-3342-4","volume":"27","author":"R Eastell","year":"2016","unstructured":"Eastell R, Dijk DJ, Small M, Greenwood A, Sharpe J, Yamada H, et al. Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trial. Osteoporos Int. 2016;27:309\u201318.","journal-title":"Osteoporos Int"},{"key":"1625_CR31","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/0091270011399080","volume":"52","author":"S Nagase","year":"2012","unstructured":"Nagase S, Ohyama M, Hashimoto Y, Small M, Kuwayama T, Deacon S. Pharmacodynamic effects on biochemical markers of bone turnover and pharmacokinetics of the cathepsin K inhibitor, ONO-5334, in an ascending multiple-dose, phase 1 study. J Clin Pharmacol. 2012;52:306\u201318.","journal-title":"J Clin Pharmacol"},{"key":"1625_CR32","volume-title":"Pharmacokinetic & Pharmacodynamic Data Analysis:Concepts and Applications","year":"2007","unstructured":"Gabrielsson J, Weiner D, editors. Pharmacokinetic & Pharmacodynamic Data Analysis:Concepts and Applications. Stockholm: Swedish Pharmaceutical Press; 2007."},{"key":"1625_CR33","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1517\/17425255.4.2.175","volume":"4","author":"M Baraldo","year":"2008","unstructured":"Baraldo M. The influence of circadian rhythms on the kinetics of drugs in humans. Expert Opin Drug Metab Toxicol. 2008;4:175\u201392.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1625_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07420520801909247","volume":"25","author":"B Bruguerolle","year":"2008","unstructured":"Bruguerolle B. Clinical chronopharmacology in the elderly. Chronobiol Int. 2008;25:1\u201315.","journal-title":"Chronobiol Int"},{"key":"1625_CR35","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1365-2036.1998.00306.x","volume":"12","author":"RA Blum","year":"1998","unstructured":"Blum RA, Hunt RH, Kidd SL, Shi H, Jennings DE, Greski-Rose PA. Dose-response relationship of lansoprazole to gastric acid antisecretory effects. Aliment Pharmacol Ther. 1998;12:321\u20137.","journal-title":"Aliment Pharmacol Ther"},{"key":"1625_CR36","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1021\/jm050915u","volume":"49","author":"DS Yamashita","year":"2006","unstructured":"Yamashita DS, Marquis RW, Xie R, Nidamarthy SD, Oh HJ, Jeong JU, et al. Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors. J Med Chem. 2006;49:1597\u2013612.","journal-title":"J Med Chem"},{"key":"1625_CR37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00198-011-1593-2","volume":"23","author":"C Jerome","year":"2012","unstructured":"Jerome C, Missbach M, Gamse R. Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. Osteoporos Int. 2012;23:339\u201349.","journal-title":"Osteoporos Int"},{"key":"1625_CR38","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1210\/jc.2013-3795","volume":"99","author":"JW Mandema","year":"2014","unstructured":"Mandema JW, Zheng J, Libanati C, Perez Ruixo JJ. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis. J Clin Endocrinol Metab. 2014;99:3746\u201355.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-017-1625-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T21:08:13Z","timestamp":1719263293000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-017-1625-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,19]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1625"],"URL":"https:\/\/doi.org\/10.1186\/s12891-017-1625-y","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,19]]},"article-number":"267"}}